NCT07254234

Brief Summary

The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
11mo left

Started Sep 2026

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Sep 2026Sep 2027

First Submitted

Initial submission to the registry

November 20, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 28, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

September 23, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

September 24, 2026

Status Verified

September 1, 2026

Enrollment Period

11 months

First QC Date

November 20, 2025

Last Update Submit

September 23, 2026

Conditions

Cognitive DysfunctionMemory Disorders

Outcome Measures

Primary Outcomes (1)

  • Percentage of Participants with the Same Results on the Blood Test and Retinal Scan

    Day 1

Secondary Outcomes (1)

  • Percentage of Participants who Report High or Moderate Satisfaction with Retinal Scan

    Day 1

Study Arms (1)

Participants with Memory Complaints or Mild Cognitive Impairment (MCI)

Retinal scan and blood biomarker testing

Other: Retinal scanOther: Blood test

Interventions

Retinal scanOTHER

Detailed image of the retina.

Participants with Memory Complaints or Mild Cognitive Impairment (MCI)
Blood testOTHER

Sample will be used to test for a specific form of a protein in the blood to learn more about early detection of Alzheimer's disease.

Participants with Memory Complaints or Mild Cognitive Impairment (MCI)

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Emiratis age 55 or older with mild memory complaints or MCI who are otherwise healthy.

You may qualify if:

  • Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination.
  • Have mild memory complaints or a diagnosis of mild cognitive impairment.
  • Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator.
  • Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.

You may not qualify if:

  • Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study.
  • Have an existing diagnosis of AD or other dementia.
  • Have contradictions to or an allergy to the ophthalmic dilating agents.
  • Current or previous treatment with anti-amyloid medications.
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Burjeel Medical City

Abu Dhabi, United Arab Emirates

NOT YET RECRUITING

Sheikh Shakhbout Medical City

Abu Dhabi, United Arab Emirates

RECRUITING

Sheikh Tahnoon Bin Mohammed Medical City

Abu Dhabi, United Arab Emirates

RECRUITING

MeSH Terms

Conditions

Cognitive DysfunctionMemory Disorders

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Eli Lilly and Company

    STUDY DIRECTOR

Central Study Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2025

First Posted

November 28, 2025

Study Start

September 23, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

September 24, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations

AE(3)